Seven biosciences is a drug discovery platform company structured around leveraging transformative technology to identify and develop novel therapeutics targeting G-protein coupled receptors (GPCRs). With Founders describing themselves as using radical technology to develop innovative therapeutics in CNS diseases, the firm's platform utilizes GPCR-based sensors which reports ligand induced changes of conformation in real-time using fluorescence to enable high throughput screening and in vitro and in vivo pharmacodynamics. With GPCR biosensors discussed by the principals as illuminating the intricacies and complexities of human GPCR signaling, making more promising drug discoveries possible, the firm's proprietary genetically encoded GPCR biosensors are designed with the molecular specificity, affinity, and kinetics similar to endogenous receptors. This - it is suggseted - make GPCR biosensors are ideal for drug discovery. Unlike traditional technologies, GPCR biosensors enable the robust, direct, and chronic detection of physiologically or behaviorally relevant activity of the GPCR of interest in response to a given compound both in vitro and in vivo.
